HbA1c Testing Devices Market To Reach $4.2 Billion by 2033

August 2026 | Report Format: Electronic (PDF)

HbA1c Testing Devices Market Growth & Trends

The global HbA1c testing devices market size is expected to reach USD 4.2 billion by 2033, registering a CAGR of 7.3% from 2026 to 2033, according to a new report by Grand View Research, Inc. The global market for HbA1c testing devices is witnessing significant growth, driven by the rising prevalence of diabetes and the demand for accurate and efficient monitoring solutions. According to the CDC, in 2021, 38.4 million Americans, or 11.6% of the population, had diabetes. This includes 2 million Americans with type 1 diabetes, approximately 304,000 of whom are children and adolescents. The report also highlights that 1.2 million Americans are diagnosed with diabetes annually, underscoring the persistent need for diabetes care and management. HbA1c testing plays a crucial role in diabetes management by providing valuable insights into long-term blood sugar control and assisting healthcare providers in optimizing patient treatment plans.

The importance of glycemic control and HbA1c testing devices drive market growth by increasing demand for accurate monitoring tools, fostering innovation, and expanding market reach, particularly in low- and middle-income countries. Inadequate control leads to complications, impacting patients' quality of life and healthcare costs. According to a study, the Diabetes Control and Complications Trial (DCCT) shows that strict glucose control reduces long-term complications, highlighting the cost-effectiveness of intensive treatment. In low- and middle-income countries (LMICs), owing to late diagnosis, glycemic control and patient education become crucial. This, in turn, propels the need for early diagnosis, systematic complication screening, and timely treatment intensification to lower costs compared to inpatient care and treatment of complications.

The market is witnessing a notable shift towards Point-of-care (POC) testing devices, which offer rapid results, enabling timely interventions and personalized treatment plans. POC devices are gaining extensive popularity in homecare settings, enabling patients to monitor their HbA1c levels conveniently and effectively. This trend reflects the growing emphasis on patient-centric care and adoption of remote monitoring solutions in healthcare.

Key market players such as ARKRAY, Inc., Abbott Laboratories, Chek, Siemens Healthineers, Danaher Corporation, Bio-Rad Laboratories, Inc., Trivitron Healthcare, EKF Diagnostics, and Tosoh Corporation are at the forefront of innovation in HbA1c testing devices. These companies are constantly focusing on developing advanced technologies to enhance the accuracy, speed, and user-friendliness of HbA1c testing devices, catering to the evolving needs of healthcare professionals and patients. For instance, in August 2022 , DxGen Corp. and Precision Diabetes, Inc. partnered to launch Epithod AutoDx, an automatic point-of-care analyzer for diabetes tests, including HbA1c. With a user-friendly design, it enables rapid results in settings such as physician offices and clinics, addressing the growing demand for on-site testing amid the pandemic.

key Request a free sample copy or view report summary: HbA1c Testing Devices Market Report

HbA1c Testing Devices Market Report Highlights

Based on type, the laboratory-based testing devices segment dominated the global HbA1c testing devices market, accounting for 54.4% of the total market revenue in 2025, driven by their widespread adoption in hospitals, diagnostic laboratories, and reference laboratories for high-volume diabetes testing.
Based on technology, the ion-exchange chromatography segment dominated the global HbA1c testing devices market, accounting for 33.6% of revenue in 2025, owing to its high analytical accuracy, excellent separation of hemoglobin fractions, effective detection of hemoglobin variants, and compatibility with automated high-throughput laboratory workflows.
Based on end use, the hospitals & clinics segment accounted for the largest revenue share of 57.1% in 2025 and remain the dominant end use segment in the HbA1c testing devices market, driven by high diabetes patient volumes, routine HbA1c monitoring, integrated laboratory infrastructure, and the availability of both centralized and point-of-care testing.
North America HbA1c testing devices industry dominated the global market and accounted for the 33.8% share in 2025, driven by a large diabetes population, well-established healthcare infrastructure, and strong adoption of laboratory-based and point-of-care HbA1c testing.